Invivyd provides preliminary Q4 results

Sees Q4 Pemgarda product revenue up 48% sequentially to $13.8M, consensus $13.87M. Sees preliminary Q4 total operating costs and expenses of $32M, a 55% reduction vs. $71.6 in Q3 2024. Sees Q4 ending 2024 cash and cash equivalents of $69.3M and $10.9M of accounts receivable. Had previously guided expectations to finish 2024 with $65M or more in cash and cash equivalents. “We are pleased with continued strong top-line revenue growth and execution toward near-term profitability,” noted CFO Bill Duke. “With a strong balance sheet, anticipated continued growth in revenues and simultaneous reduction in operating expenses, we are well-positioned to support Pemgarda commercial efforts and look forward to the future of VYD2311.”